Suppression of autoreactive T-cell response to glycoprotein IIb/IIIa by blockade of CD40/CD154 interaction: implications for treatment of immune thrombocytopenic purpura

被引:32
作者
Kuwana, M
Kawakami, Y
Ikeda, Y
机构
[1] Keio Univ, Sch Med, Inst Adv Med Res, Shinjuku Ku, Tokyo 1608582, Japan
[2] Keio Univ, Sch Med, Dept Internal Med, Shinjuku Ku, Tokyo 1608582, Japan
关键词
D O I
10.1182/blood-2002-07-2157
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The potential immunosuppressive effect of an anti-CD154 monoclonal antibody (mAb) on the pathogenic autoreactive T-cell response was evaluated using an in vitro culture system with glycoprotein IIb/IIIa (GPIIb/IIIa)-reactive T cells from patients with immune thrombocytopenic purpura (ITP). The anti-CD154 mAb did not inhibit T-cell proliferation, but suppressed anti-GPIIb/IIIa antibody production, in bulk peripheral blood mono-nuclear. cell cultures stimulated with GPIIb/IIIa. Repeated antigenic stimulation of GPIIb/IIIa-reactive CD4(+) T-cell lines in the presence of anti-CD154 mAb resulted in the loss of proliferative capacity and helper function for promoting anti-GPIIb/IIIa antibody production. These anergic T-cell lines showed a cytokine profile of low interferon gamma and high interleukin 10 and suppressed anti-GPIIb/IIIa antibody production. Our results indicate that blockade of the CD40/CD154 interaction induces generation of autoantigen-specific anergic CD4(+) T cells with regulatory function and could be a therapeutic option for suppressing pathogenic autoimmune responses in patients with ITP. (C) 2003 by The American Society of Hematology.
引用
收藏
页码:621 / 623
页数:3
相关论文
共 26 条
[1]   CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism [J].
André, P ;
Prasad, KSS ;
Denis, CV ;
He, M ;
Papalia, JM ;
Hynes, RO ;
Phillips, DR ;
Wagner, DD .
NATURE MEDICINE, 2002, 8 (03) :247-252
[2]   Autoreactive CD4+ T-cell clones to β2-glycoprotein I in patients with antiphospholipid syndrome:: preferential recognition of the major phospholipid-binding site [J].
Arai, T ;
Yoshida, K ;
Kaburaki, J ;
Inoko, H ;
Ikeda, Y ;
Kawakami, Y ;
Kuwana, M .
BLOOD, 2001, 98 (06) :1889-1896
[3]   A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation [J].
Brams, P ;
Black, A ;
Padlan, EA ;
Hariharan, K ;
Leonard, J ;
Chambers-Slater, K ;
Noelle, RJ ;
Newman, R .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (02) :277-294
[4]   Medical progress: Immune thrombocytopenic purpura. [J].
Cines, DB ;
Blanchette, VS .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (13) :995-1008
[5]   CD40-CD40 ligand interaction in autoimmune disease [J].
Datta, SK ;
Kalled, SL .
ARTHRITIS AND RHEUMATISM, 1997, 40 (10) :1735-1745
[6]  
Davis JC, 2001, J RHEUMATOL, V28, P95
[7]   A CD4(+) T-cell subset inhibits antigen-specific T-cell responses and prevents colitis [J].
Groux, H ;
OGarra, A ;
Bigler, M ;
Rouleau, M ;
Antonenko, S ;
deVries, JE ;
Roncarolo, MG .
NATURE, 1997, 389 (6652) :737-742
[8]   The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40 [J].
Henn, V ;
Steinbach, S ;
Büchner, K ;
Presek, P ;
Kroczek, RA .
BLOOD, 2001, 98 (04) :1047-1054
[9]   CD40L blockade prevents autoimmune diabetes by induction of bitypic NK/DC regulatory cells [J].
Homann, D ;
Jahreis, A ;
Wolfe, T ;
Hughes, A ;
Coon, B ;
van Stipdonk, MJB ;
Prilliman, KR ;
Schoenberger, SP ;
von Herrath, MG .
IMMUNITY, 2002, 16 (03) :403-415
[10]   Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis [J].
Howard, LM ;
Miga, AJ ;
Vanderlugt, CL ;
Dal Canto, MC ;
Laman, JD ;
Noelle, RJ ;
Miller, SD .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (02) :281-290